Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
S S Cohen,
R M RM Levy,
M M Keller,
E E Boling,
R D RD Emkey,
M M Greenwald,
T M TM Zizic,
S S Wallach,
K L KL Sewell,
B P BP Lukert,
D W DW Axelrod and
A A AA Chines
Arthritis Rheum 42(11):2309-18 (1999)
PMID 10555025
Risedronate, a new pyridinyl bisphosphonate, is a potent antiresorptive bone agent. This study examines the safety and efficacy of daily, oral risedronate therapy for the prevention of corticosteroid-induced bone loss.
DOI: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
Version: za2963e q8za8 q8zbd q8zc3 q8zd6 q8zea q8zfd q8zgc
